Stock Report: Warner Chilcott Plc (WCRX) Report Updated: Jun 17, 2013 | Print This Page

Warner Chilcott Public Limited Company, a specialty pharmaceutical company, together with its subsidiaries, engages in the development, manufacture, and promotion of branded pharmaceutical products focusing on the women’s healthcare, gastroenterology, dermatology, and urology markets in North America and western Europe. Its principal products include ACTONEL for the prevention and treatment of postmenopausal osteoporosis; ATELVIA for the treatment of postmenopausal osteoporosis; LOESTRIN 24 FE and LO LOESTRIN FE, which are oral contraceptives for the prevention of pregnancy; ESTRACE cream, a vaginal cream for the treatment of vaginal and vulvar atrophy; ASACOL for the treatment of ulcerative colitis for orally administered 5-aminosalicylic acid products and maintenance of remission; ASACOL HD for the treatment of moderately active ulcerative colitis; DORYX, a tetracycline-class oral antibiotic for the treatment of severe acne; and ENABLEX for the treatment of overactive bladder. The company markets its products and services through wholesale pharmaceutical distributors, and retail drug store chains. It has a strategic collaboration agreement with Sanofi-Aventis U.S. LLC. Warner Chilcott Public Limited Company was founded in 1968 and is headquartered in Dublin, Ireland.